MEP24508A - Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use - Google Patents

Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use

Info

Publication number: MEP24508A
Authority: ME; Montenegro
Prior art keywords: preparation; phenylsulfonyl; indole; dihydro; derivatives
Prior art date: 2001-07-17

Application number

MEP-245/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Malta Alain Di

Georges Garcia

Richard Roux

Bruno Schoentjes

Gal Claudine Serradeil-Le

Bernard Tonnerre

Jean Wagnon

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-17

Filing date

2002-07-15

Publication date

2010-10-10

2002-07-15 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-10-10 Publication of MEP24508A publication Critical patent/MEP24508A/xx

Links

HBORMJBGPGQHSF-UHFFFAOYSA-N 1-(benzenesulfonyl)-3h-indol-2-one Chemical class O=C1CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 HBORMJBGPGQHSF-UHFFFAOYSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
101800001144 Arg-vasopressin Proteins 0.000 abstract 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000007524 organic acids Chemical class 0.000 abstract 1
235000005985 organic acids Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Addiction (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)

MEP-245/08A 2001-07-17 2002-07-15 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use MEP24508A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0110359A FR2827604B1 (fr)	2001-07-17	2001-07-17	Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
PCT/FR2002/002500 WO2003008407A2 (fr)	2001-07-17	2002-07-15	Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
MEP24508A true MEP24508A (en)	2010-10-10

Family

ID=8866211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-245/08A MEP24508A (en)	2001-07-17	2002-07-15	Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use

Country Status (31)

Country	Link
US (1)	US7119086B2 (sr)
EP (1)	EP1419150B1 (sr)
JP (1)	JP4262088B2 (sr)
KR (1)	KR20040017325A (sr)
CN (1)	CN1224623C (sr)
AR (1)	AR034792A1 (sr)
AT (1)	ATE294171T1 (sr)
AU (1)	AU2002340999B2 (sr)
BR (1)	BR0211284A (sr)
CA (1)	CA2450437A1 (sr)
CO (1)	CO5550440A2 (sr)
DE (1)	DE60203917T2 (sr)
DK (1)	DK1419150T3 (sr)
EA (1)	EA006019B1 (sr)
ES (1)	ES2240814T3 (sr)
FR (1)	FR2827604B1 (sr)
HR (1)	HRP20040027A2 (sr)
HU (1)	HUP0401461A3 (sr)
IL (1)	IL159275A0 (sr)
IS (1)	IS2485B (sr)
MA (1)	MA27049A1 (sr)
ME (1)	MEP24508A (sr)
MX (1)	MXPA04000507A (sr)
NO (1)	NO20040219L (sr)
NZ (1)	NZ530144A (sr)
PL (1)	PL366829A1 (sr)
PT (1)	PT1419150E (sr)
RS (1)	RS204A (sr)
UA (1)	UA77181C2 (sr)
WO (1)	WO2003008407A2 (sr)
ZA (1)	ZA200309717B (sr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754711B2 (en) *	2003-07-30	2010-07-13	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
RU2259999C2 (ru) *	2003-08-26	2005-09-10	ООО "Исследовательский институт химического разнообразия"	1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
WO2005018531A2 (en) *	2003-08-26	2005-03-03	'chemical Diversity Research Institute', Ltd.	Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
JP4618127B2 (ja)	2003-08-28	2011-01-26	大正製薬株式会社	１，３−ジヒドロ−２ｈ−インドール−２−オン誘導体
US8580842B2 (en) *	2003-09-30	2013-11-12	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MXPA06012403A (es)	2004-04-27	2007-01-17	Wyeth Corp	Purificacion de moduladores de receptor progesterona.
DE102004033834A1 (de) *	2004-07-13	2006-02-02	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
US20080227802A1 (en) *	2004-12-27	2008-09-18	Kyoto University	Agent For Suppressing Development of Tolerance to Narcotic Analgesics
WO2006080574A1 (ja) *	2005-01-28	2006-08-03	Taisho Pharmaceutical Co., Ltd.	１，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
WO2006100082A2 (de)	2005-03-24	2006-09-28	Abbott Gmbh & Co. Kg	Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014936A1 (de) *	2005-03-24	2006-12-14	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014904A1 (de) *	2005-03-26	2007-02-01	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US7576082B2 (en)	2005-06-24	2009-08-18	Hoffman-La Roche Inc.	Oxindole derivatives
SG132540A1 (en)	2005-11-25	2007-06-28	Matsushita Electric Industrial Co Ltd	Magnetic trap for ferrous contaminants in lubricant
CN101336239A (zh) *	2005-12-02	2008-12-31	艾博特股份有限两合公司	经取代的羟吲哚衍生物，含有该衍生物的药物及其用途
DE102006040915A1 (de) *	2006-08-26	2008-03-20	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TWI403508B (zh) *	2006-08-26	2013-08-01	Abbott Gmbh & Co Kg	經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途
US8486979B2 (en)	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) *	2006-12-12	2008-07-10	Abbott Laboratories	Pharmaceutical compositions and their methods of use
UY30846A1 (es)	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CN101611028B (zh) *	2006-12-30	2013-09-11	艾博特股份有限两合公司	取代的羟吲哚衍生物、以及它们用作加压素受体配体的用途
US8486931B2 (en) *	2007-03-02	2013-07-16	Abbott Gmbh & Co. Kg	Substituted oxindole compounds
FR2920023B1 (fr) *	2007-08-16	2013-02-08	Sanofi Aventis	Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
KR20100097195A (ko)	2007-12-07	2010-09-02	애보트 게엠베하 운트 콤파니 카게	５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
WO2009071691A2 (de) *	2007-12-07	2009-06-11	Abbott Gmbh & Co. Kg	Oxindol-derivate und ihre verwendung als medikament
JP5701607B2 (ja)	2007-12-07	2015-04-15	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
EP2231644B1 (de) *	2007-12-07	2014-01-15	AbbVie Deutschland GmbH & Co KG	5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
WO2010009775A1 (de)	2007-12-07	2010-01-28	Abbott Gmbh & Co. Kg	Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MY157425A (en) *	2007-12-27	2016-06-15	Abbvie Deutschland	Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) *	2008-02-19	2010-03-12	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) *	2008-04-21	2010-05-14	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
WO2010017827A1 (en) *	2008-08-14	2010-02-18	European Molecular Biology Laboratory	6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
CN102256618A (zh)	2008-10-17	2011-11-23	赛诺菲-安万特德国有限公司	胰岛素和glp-1激动剂的组合
FR2941946B1 (fr)	2009-02-12	2011-03-25	Sanofi Aventis	Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2941947B1 (fr) *	2009-02-12	2011-03-25	Sanofi Aventis	Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
EP2435080A2 (en)	2009-05-29	2012-04-04	Abbott Laboratories	Pharmaceutical compositions for the treatment of pain
CN102573836A (zh) *	2009-06-10	2012-07-11	雅培股份有限两合公司	取代的羟吲哚衍生物治疗和预防疼痛的应用
PL2451437T3 (pl)	2009-07-06	2017-05-31	Sanofi-Aventis Deutschland Gmbh	Wodne preparaty insuliny zawierające metioninę
TR201809460T4 (tr)	2009-11-13	2018-07-23	Sanofi Aventis Deutschland	Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en)	2009-11-13	2013-09-27	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
US8088815B2 (en)	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8288431B2 (en)	2010-02-17	2012-10-16	Hoffmann-La Roche Inc.	Substituted spiroindolinones
US8217044B2 (en)	2010-04-28	2012-07-10	Hoffmann-La Roche Inc.	Spiroindolinone pyrrolidines
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
WO2012028172A1 (en)	2010-08-30	2012-03-08	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103380127B (zh)	2010-12-21	2016-08-10	拜耳知识产权有限责任公司	制备n-磺酰基取代的羟吲哚的方法
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2983697B1 (en)	2013-04-03	2018-10-31	Sanofi	Treatment of diabetes mellitus by long acting formulations of insulins
PE20171622A1 (es)	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
EP3912625A1 (en) *	2020-05-20	2021-11-24	Kaerus Bioscience Limited	Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
KR20230090589A (ko) *	2021-12-15	2023-06-22	국립해양생물자원관	성게 유래 펩타이드 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2714378B1 (fr)	1993-12-24	1996-03-15	Sanofi Sa	Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
GB2326639A (en) *	1997-06-18	1998-12-30	Merck & Co Inc	Piperazine Oxytocin Receptor Antagonists
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

2001
- 2001-07-17 FR FR0110359A patent/FR2827604B1/fr not_active Expired - Fee Related
2002
- 2002-07-15 UA UA20031212069A patent/UA77181C2/uk unknown
- 2002-07-15 WO PCT/FR2002/002500 patent/WO2003008407A2/fr not_active Ceased
- 2002-07-15 HR HR20040027A patent/HRP20040027A2/xx not_active Application Discontinuation
- 2002-07-15 AU AU2002340999A patent/AU2002340999B2/en not_active Ceased
- 2002-07-15 US US10/484,370 patent/US7119086B2/en not_active Expired - Fee Related
- 2002-07-15 DE DE60203917T patent/DE60203917T2/de not_active Expired - Lifetime
- 2002-07-15 IL IL15927502A patent/IL159275A0/xx unknown
- 2002-07-15 JP JP2003513966A patent/JP4262088B2/ja not_active Expired - Fee Related
- 2002-07-15 DK DK02774822T patent/DK1419150T3/da active
- 2002-07-15 EP EP02774822A patent/EP1419150B1/fr not_active Expired - Lifetime
- 2002-07-15 PL PL02366829A patent/PL366829A1/xx not_active Application Discontinuation
- 2002-07-15 BR BR0211284-1A patent/BR0211284A/pt not_active IP Right Cessation
- 2002-07-15 ME MEP-245/08A patent/MEP24508A/xx unknown
- 2002-07-15 EA EA200301306A patent/EA006019B1/ru not_active IP Right Cessation
- 2002-07-15 KR KR10-2004-7000787A patent/KR20040017325A/ko not_active Abandoned
- 2002-07-15 CN CNB028142624A patent/CN1224623C/zh not_active Expired - Fee Related
- 2002-07-15 CA CA002450437A patent/CA2450437A1/en not_active Abandoned
- 2002-07-15 NZ NZ530144A patent/NZ530144A/en not_active IP Right Cessation
- 2002-07-15 MX MXPA04000507A patent/MXPA04000507A/es active IP Right Grant
- 2002-07-15 HU HU0401461A patent/HUP0401461A3/hu unknown
- 2002-07-15 ES ES02774822T patent/ES2240814T3/es not_active Expired - Lifetime
- 2002-07-15 PT PT02774822T patent/PT1419150E/pt unknown
- 2002-07-15 AT AT02774822T patent/ATE294171T1/de active
- 2002-07-15 RS YU204A patent/RS204A/sr unknown
- 2002-07-16 AR ARP020102655A patent/AR034792A1/es unknown
2003
- 2003-12-15 ZA ZA200309717A patent/ZA200309717B/en unknown
- 2003-12-15 IS IS7079A patent/IS2485B/is unknown
2004
- 2004-01-09 MA MA27476A patent/MA27049A1/fr unknown
- 2004-01-14 CO CO04002002A patent/CO5550440A2/es not_active Application Discontinuation
- 2004-01-16 NO NO20040219A patent/NO20040219L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0401461A2 (hu)	2004-12-28
EP1419150A2 (fr)	2004-05-19
ES2240814T3 (es)	2005-10-16
EA006019B1 (ru)	2005-08-25
CA2450437A1 (en)	2003-01-30
ZA200309717B (en)	2004-12-15
UA77181C2 (en)	2006-11-15
PL366829A1 (en)	2005-02-07
IS2485B (is)	2008-12-15
EA200301306A1 (ru)	2004-06-24
FR2827604B1 (fr)	2003-09-19
DE60203917D1 (de)	2005-06-02
US7119086B2 (en)	2006-10-10
AU2002340999B2 (en)	2007-03-01
RS204A (sr)	2006-12-15
PT1419150E (pt)	2005-08-31
DK1419150T3 (da)	2005-08-29
IS7079A (is)	2003-12-15
JP4262088B2 (ja)	2009-05-13
US20040180878A1 (en)	2004-09-16
HRP20040027A2 (en)	2004-06-30
CN1224623C (zh)	2005-10-26
KR20040017325A (ko)	2004-02-26
IL159275A0 (en)	2004-06-01
JP2004536131A (ja)	2004-12-02
DE60203917T2 (de)	2006-02-16
WO2003008407A3 (fr)	2003-10-16
HUP0401461A3 (en)	2009-06-29
CN1533387A (zh)	2004-09-29
CO5550440A2 (es)	2005-08-31
NZ530144A (en)	2005-03-24
HK1061679A1 (en)	2004-09-30
BR0211284A (pt)	2004-08-03
WO2003008407A2 (fr)	2003-01-30
MXPA04000507A (es)	2004-07-23
NO20040219L (no)	2004-03-17
FR2827604A1 (fr)	2003-01-24
AR034792A1 (es)	2004-03-17
MA27049A1 (fr)	2004-12-20
EP1419150B1 (fr)	2005-04-27
ATE294171T1 (de)	2005-05-15

Publication	Publication Date	Title
MEP24508A (en)	2010-10-10	Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
EA200200628A1 (ru)	2002-12-26	Новые производные 1,3-дигидро-2н-индол-2-она и их применение в качестве лигандов рецепторов аргинин-вазопрессина v1b и v1a
PA8582801A1 (es)	2004-05-26	Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
PT1254134E (pt)	2003-11-28	Derivados de 1,3-di-hidro-2h-indol-2-ona e sua utilizacao como ligandos para os receptores v1b ou v1b e v1a da arginina-vasopressina
EA200200912A1 (ru)	2003-06-26	Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина
BG107171A (bg)	2003-07-31	Производни на пурин
MEP45308A (en)	2011-02-10	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ECSP066541A (es)	2006-12-20	Nuevos derivados de piridazin-3(2h)-ona
CY1109765T1 (el)	2014-09-10	Αζα- δικυκλοαλκυλο αιθερες και η χρηση τους ως αγωνιστες aλφα7-nachr
HRP20040618B1 (hr)	2013-07-31	Supstituirani 2-tio-3,5-dicijano-4-fenil-6-aminopiridini i njihova upotreba
ATE292118T1 (de)	2005-04-15	Pyrazolderivative als p-38 map kinase inhibitoren
BRPI0407811A (pt)	2006-02-14	composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
AR029942A1 (es)	2003-07-23	Compuestos derivados de 1,3-dihidro-2h-indol-2-ona, su utilizacion, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden, medicamentos constituidos por dichos compuestos y compuestos intermediarios
SE0403171D0 (sv)	2004-12-23	New compounds
HRP20041030B1 (hr)	2013-03-31	Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba
BR0012478A (pt)	2002-04-02	Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
EA200400848A1 (ru)	2004-12-30	Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
YU44301A (sh)	2004-07-15	5ht1 antagonisti za antidepresantnu terapiju
ECSP067111A (es)	2007-01-26	Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
MEP11908A (en)	2010-06-10	(1-phenacy-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
ATE274515T1 (de)	2004-09-15	Pyrazolopyridinderivate
YU68201A (sh)	2004-03-12	Novi derivati morfolina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
EA200400847A1 (ru)	2004-12-30	Производные имидазохинолина
BR0308223A (pt)	2005-06-28	Derivados de piridiniloxi como ligantes de receptor 5-ht
GT200600298A (es)	2007-07-10	Derivados de n-[(4,5-difenilpirimidin-2-il)metil] amina, su preparacion y su aplicacion en terapeutica